OBIO operates within a good governance framework and is accountable to its members and stakeholders
Board of Directors
Jeremy Bridge-Cook, OBIO Chair
CEO, RNA Diagnostics
Dr. Bridge-Cook was named Senior Vice President of Research and Development in May 2012. Previously he served as Senior Vice President of the Assay Group and Vice President, Luminex Molecular Diagnostics. He also served at Tm Bioscience, which became Luminex Molecular Diagnostics following the acquisition of Tm Bioscience by Luminex in March 2007. Dr. Bridge-Cook joined Tm Bioscience in July 2000 as Director of Business Development and served in various capacities thereafter, including Vice President of Business Development, Vice President of Marketing & Business Development, and Senior Vice President of Corporate Development. Prior to joining Tm, Dr. Bridge-Cook worked as a venture capital investment analyst at MDS Capital Corporation and University Medical Discoveries Inc. Dr. Bridge-Cook has a Ph.D. in immunology from the University of Toronto.
Gail Garland, OBIO Director
Chief Executive Officer
Ontario Bioscience Innovation Organization (OBIO)
Gail Garland is the founder and CEO of OBIO®, a not-for-profit, membership-based organization championing the development of an integrated health innovation economy for Ontario.
Gail established OBIO in partnership with dozens of like-minded industry CEOs to advance the goal of making Ontario into a world-leading health innovation sector where health science companies will flourish, as well as a global leader in providing health technology products and services to the international marketplace.
Since 2009, OBIO has developed and implemented a province-wide strategic vision called OBEST (Ontario Bioscience Economic Strategy Team). Building from that strategy, OBIO published a series of white papers – in collaboration with industry executives, health system leaders, and academics – that identify the highest priority issues facing Ontario’s health science economy, like access to capital, access to industry-ready business talent, and innovation adoption. OBIO’s reports led directly to the establishment of OBIO solutions-focused programming, like CAAP® (Capital Access Advisory Program) in 2013 to increase deal flow for high potential early stage companies, Pre-CAAP in 2015 to help boost investability of seed stage companies, and H2BB™, the Health to Business Bridge™ internship program in 2016, which combines OBIO’s deep-rooted relationships across academia and industry to improve access to industry-ready business talent.
Gail serves on the Board of Governors for Carleton University; the Dean’s Advisory Council, Faculty of Science, at Ryerson University; the Biotechnology Advisory Committee at Humber College; the Canadian Life Sciences Advisory Counsel for Springboard Enterprises; and the Advisory Board for the Centre for Bioengineering and Biotechnology, University of Waterloo. Gail is the Industry Chair of the OBIO MPP Health Sciences Caucus and serves on the Conference Board of Canada’s Council for Innovation Procurement in Healthcare. She has advocated for the future of the health science industry on national television (Business News Network) and has also written extensively on the topic, with numerous publications in both the national press (The Globe and Mail) and international industry publications (Biotechnology Focus).
Before starting OBIO, Gail had more than twenty years of industry experience, including senior roles in banking, pharmaceuticals, biotech and in the medical devices sector. Gail holds a Chartered Director (CDir) designation in governance (McMaster), an MBA from the Rotman School of Management (University of Toronto), and a BSc. (Carleton University). Gail is a recipient of the Arbor Award for Exceptional Volunteer Service to the University of Toronto and in 2017 she was named one of Carleton University’s seventy-five best graduates in celebration of the school’s 75th anniversary.
Michael Cloutier, OBIO Board Director
Canadian Partner, Mirador Global
Michael Cloutier is an executive leader and human resources strategist with demonstrated success at national and global levels within the pharmaceutical, biotech and health sciences industries. Michael identifies, initiates and creates strategic plans for organizational transformation and performance enhancement, while delivering results through building and maintaining strong relationships internally and externally across all stakeholder populations. He is recognized as a focused and ethical leader who demonstrates linear and abstract thinking to meet and exceed the needs of an organization.
Shelley Boyd, OBIO Director
CEO, Translatum Medicus
Shelley Boyd, MD, FRCSC, is an Ophthalmologist specializing in diseases of the retina. She trained at the University of Toronto, with fellowships at Moorfields Eye Hospital, UK and the Scripps Research Institute, California. She is director of the Ocular Phenotyping Facility of the Toronto Centre for Phenogenomics, and the Walter Retinal Regeneration laboratory. She is Assistant Professor of Ophthalmology & Vision Sciences, with cross-appointment to Biomedical Engineering, McMaster University. Shelley was formerly Head of the Ocular Angiogenesis Research Program, worldwide, with Novartis (Switzerland), overseeing pre-clinical and translational aspects of the Ranibizumab program.
Adam Buckley, OBIO Director
Vice President, Operations, VBI Vaccines
Adam Buckley co-founded VBI Vaccines in 2002. He has been responsible for a number of roles through VBI’s development stages, including business development, corporate development, finance and operations. His efforts included attracting seed capital to VBI, developing its first business plan, protecting intellectual property and structuring the company. He had an active role in the company’s Series A financing, raising $35.7 million (U.S.), and has led several key technology acquisitions for the company, including the acquisition of Epixis S.A. in 2011 which provided VBI with one of its core platform technologies. Most recently, Adam has held operational responsibilities for the company’s research and development site in Ottawa, Canada, leading efforts for the efficient and milestone driven development of the company’s vaccine products and platforms. Mr. Buckley is a recent recipient of the Ottawa Business Journal’s “Top 40 Under 40” award and obtained his M.B.A. and B.Sc. at McMaster University in Hamilton, Ontario.
M. Cynthia Goh, OBIO Director
Academic Director, Banting and Best Innovation Center
M. Cynthia Goh is Professor at the Department of Chemistry, the Institute of Medical Science, the Munk School of Global Affairs, and Academic Director, Banting and Best Innovation Center. She received her PhD from the University of California at Los Angeles, and carried out postdoctoral fellowships at Columbia University and the University of California, Berkeley, prior to taking a faculty position at the University of Toronto. She has a diverse set of research interests, including fundamental studies of complex systems biomaterials, interfaces, probe microscopy, the development of new research instrumentation and nanotechnology. She is also known for her interest the translation of scientific discovery to technology and products, and the education of scientist-entrepreneurs. Together with her students, she co-founded 6 companies including Axela Inc, Vive Crop Protection and Sciventions, as well as Entrepreneurship101 at MaRS, the flagship entrepreneur training program of the MaRS Discovery District, with thousands registered attendees annually. In 2010, she introduced Techno, a one-month intensive training program specifically geared for university scientists intending to build a tech-based company. Techno programs from 2010 to 2014 have led to the creation of over 60 start-ups based on the results of scientific research, many of which now have sales and follow-on funding.
Kelly Holman, OBIO Director
Co-Founder and Managing Director, Genesys Capital
Mr. Holman is co-Founder and Managing Director of Genesys Capital. Since co-founding the firm in 2000, Mr. Holman has been actively involved in raising over $225 million of venture capital and has been instrumental in deploying over $150 million across 28 investments. He currently serves on the Board of Directors of Functional Neuromodulation, Impopharma and InVitae (observer). From 2001-2013, Kelly served on the Board of Directors of Epocal (acquired by Alere in 2013). Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen’s University.
Richard Meadows, OBIO Director
Venture Capital Professional
Richard Meadows was selected by FORBES as one of the top ten Life Science Investors in North America in 2013. He was a Managing Partner, and co-founder of CTI Capital, Fund I, a $100M Life Sciences Fund in Canada that co-lead financings in ENOBIA (exit for $1.081B) and TARGEGEN (exit for $565M). He joined the Fund from his previous position as a Venture Partner with Vantage Point Venture Partners (VPVP), a US$2.8 billion private Equity fund based in San Bruno, California. Prior to VPVP, Richard was also a Partner in the Biotechnology Group of CDP Capital Technology Ventures ($1.2 billion). Richard is currently raising a BioInnovation Capital Fund and in parallel has been raising money for start-ups in the med device space; and an early stage speciality pharma company in Europe ($64M USD closed May 2018).
Terry McCool, OBIO Director
VP Corporate Affairs, Eli Lilly Canada (retired)
Mr. D. Terry McCool is the Vice President of Corporate Affairs at Eli Lilly Canada. In this role he is responsible for all aspects of corporate affairs including federal and provincial government affairs, policy development, provincial and private reimbursement , pricing, health economics, advocacy relations, communications, strategic partnerships and public affairs. Since joining Eli Lilly Canada, Mr. McCool has held various senior management positions including Director of Sales and Director of Human Resources. He is also a member of the Senior Management Team and the Board of Directors of Eli Lilly Canada. Mr. McCool sits on a number of industry association committees at the Pharmaceutical Research and Manufacturers of America (PhRMA) and Canada’s Research-Based Pharmaceutical Companies (Rx&D). He is Chair of the Intellectual Property Committee at Rx&D, and Chair of the Canada Committee at PhRMA, a Director and Member of the Executive Committee at the Institute of Health Economics in Alberta, a member of the Dean’s Advisory Committee for the University of Alberta’s Faculty of Pharmacy and a member of the Life Sciences Advisory Board for the Department of Foreign Affairs and International Trade. He also chairs the Ottawa Liaison Committee for the Chamber of Commerce in Ottawa. Mr. McCool has a Bachelor of Science in Pharmacy from the University of Alberta and attended the Advanced Management program at Kelley School of Business at Indiana University.
Steven Plymale, OBIO Director
CEO, MyndTec Inc.
Steven Plymale is the CEO of MyndTec Inc. a company dedicated to improving the quality of life of stroke and spinal cord injury patients. Prior to MyndTec Mr. Plymale led Profound Medical a company commercializing image guided ablation technology to treat prostate cancer and other diseases. Mr. Plymale guided the company through its startup phase to become a publicly traded company on the Toronto Venture exchange. Mr. Plymale’s 25 year career has included executive roles with Natus Medical, CryoCath Technologies, Claron and other notable medical device companies. Mr. Plymale is also active in corporate governance having completed the Directors Education Program at Rotman’s School of Management. He has been an active member of the Institute of Corporate Directors since 2007 and serves on several Boards across the Life Science community Canada. He is also an advisor to several industry and government support organizations including MaRS, BioMed Zone and Global Affairs Canada.
Mark Steedman, OBIO Director
President & CEO, Fibrocor Therapeutics
Mark Steedman is the president and CEO of Fiborcor Therapeutics and serves as a member of Fibrocor’s board of directors. Fibrocor’s mandate is to develop first-in-class therapeutics to target fibrotic diseases, and is supported through its founding partners MaRS Innovation (MI) and Evotec AG in Germany. Previously, Mark coordinated the formation of Interface Biologics in December 2001 and in 2004 raised $12M in a Series A round and grew the team from 0 to 15 people and helped recruit the senior management team. Mark was instrumental in landing early deals with several large medical device manufacturers, and oversaw company operations from early R&D to its first revenues in 2004. These early deals ultimately led to FDA approval for multiple medical device products. Mark holds degrees in Applied Science in Engineering, a Bachelor of Arts in Biology both from Queen’s University and an MBA from Wilfrid Laurier University.
Jung-Kay Chiu, OBIO Secretary
Partner, Norton Rose LLP
Jung-Kay Chiu practises in all areas of intellectual property law, with a focus on intellectual property acquisition, protection and exploitation in the field of biotechnology and medical devices. Mr. Chiu’s practice includes drafting and prosecuting patent applications, industrial designs and trade-marks, as well as patent licensing and other commercial transactions relating to intellectual property. Mr. Chiu is also routinely involved in preparing patent-related due diligence reports and patentability, infringement and validity opinions.
Mr. Chiu joined the Norton Rose Toronto office in 2003 after practicing corporate commercial law and intellectual property law with another major law firm in Canada. His technical experience includes conducting post-graduate research in molecular biology at the University of Toronto, and his technical background includes genetics, molecular biology, biotechnology and biochemistry. Mr. Chiu is Canadian Team Leader of the Patents and IP Transaction team.
Prabh (Bob) Singh, OBIO Treasurer
Prabh (Bob) Singh is an associate partner in the Tax Services practice of Price Waterhouse Coopers LLP working in the Mississauga office. As an associate partner in Corporate Tax Services, Bob delivers high quality value-added tax solutions by focusing on the goals and objectives of his clients. He has extensive experience in various aspects of Canadian federal and provincial income and capital taxes, including domestic tax planning and corporate reorganizations. Bob provides tax planning and compliance services for both medium-sized businesses and subsidiaries of large multinational corporations primarily in the pharmaceuticals and life sciences. He is very familiar with PwC’s service offerings and always looks for opportunities to link relevant PwC specialists to meet the needs of his clients.
He has been heavily involved in helping his pharmaceutical and life sciences clients maximize their tax incentive claims under both the federal and provincial Scientific Research and Experimental Development (SR&ED) programs. In this role, he assists clients with the review of the financial aspects of their SR&ED claims. He also coordinates with PwC’s SR&ED engineers to address the scientific aspects of the SR&ED claim. Bob is a member of the Institute of Chartered Accountants of Ontario and a University of Toronto alumnus.